{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T06:07:01Z","timestamp":1770617221386,"version":"3.49.0"},"reference-count":36,"publisher":"Akademiai Kiado Zrt.","issue":"3","license":[{"start":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:00:00Z","timestamp":1642291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2022,1,16]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold> A jelenlegi hazai gyakorlatban sokszor indokolatlanul\n                    korl\u00e1tozz\u00e1k a vesebetegek kontrasztanyagos vizsg\u00e1lat\u00e1t, \u00e9s halaszt\u00f3dik a\n                    metformint szed\u0151k vizsg\u00e1lata is, kontrasztanyag \u00e1ltal okozott akut\n                    vesek\u00e1rosod\u00e1st\u00f3l (contrast-induced acute kidney injury, CI-AKI) tartva.\n                    \u00d6sszefoglal\u00f3nk c\u00e9lja az ezzel kapcsolatos \u00fajabb ismeretek \u00e1ttekint\u00e9se \u00e9s egy\n                    szakmai javaslat ismertet\u00e9se annak \u00e9rdek\u00e9ben, hogy a betegell\u00e1t\u00e1s szempontj\u00e1b\u00f3l\n                    fontos vizsg\u00e1latok ne maradjanak el, ugyanakkor azok a maxim\u00e1lis betegbiztons\u00e1g\n                    jegy\u00e9ben k\u00e9sz\u00fcljenek. Az elm\u00falt \u00e9vek tanulm\u00e1nyai alapj\u00e1n a CI-AKI el\u0151fordul\u00e1sa a\n                    kor\u00e1bbin\u00e1l kev\u00e9sb\u00e9 gyakori, \u00e9s jelent\u0151sen k\u00fcl\u00f6nb\u00f6z\u0151 a kontrasztanyag intrav\u00e9n\u00e1s\n                    vagy intraarteri\u00e1lis alkalmaz\u00e1s\u00e1t\u00f3l f\u00fcgg\u0151en. Legfontosabb rizik\u00f3t\u00e9nyez\u0151je a\n                    cs\u00f6kkent glomerulusfiltr\u00e1ci\u00f3s r\u00e1ta (GFR), mely stabil \u00e1llapot\u00fa vesebetegn\u00e9l,\n                    intrav\u00e9n\u00e1s kontrasztanyag ad\u00e1sakor 30 ml\/min\/1,73 m<jats:sup>2<\/jats:sup> alatt,\n                    intraarteri\u00e1lis alkalmaz\u00e1sakor 45 ml\/min\/1,73 m<jats:sup>2<\/jats:sup> alatt k\u00e9pez magas\n                    rizik\u00f3t. Proteinuria eset\u00e9n a CI-AKI \u00e9s a kontrasztanyaggal t\u00e1rsult akut\n                    vesek\u00e1rosod\u00e1s (contrast-associated kidney injury, CA-AKI) kock\u00e1zata is nagyobb,\n                    ez\u00e9rt a sz\u00e1m\u00edtott GFR mellett indokolt a vizelet albumin\/kreatinin vagy\n                    feh\u00e9rje\/kreatinin h\u00e1nyados meghat\u00e1roz\u00e1sa is a vizsg\u00e1lat el\u0151tt. Az instabil\n                    \u00e1llapot, az akut veseel\u00e9gtelens\u00e9g mindenkor magas kock\u00e1zatot jelent, ilyenkor a\n                    sz\u00e1m\u00edtott GFR pontatlan, nem haszn\u00e1lhat\u00f3. Cs\u00f6kkent vesefunkci\u00f3 mellett figyelni\n                    kell a beadott kontrasztanyag mennyis\u00e9g\u00e9re, a vizsg\u00e1lat 48\u201372 \u00f3r\u00e1n bel\u00fcli\n                    ism\u00e9tl\u00e9s\u00e9nek ker\u00fcl\u00e9s\u00e9re, a nemszteroid gyullad\u00e1sg\u00e1tl\u00f3k vagy m\u00e1s nephrotoxicus\n                    szerek lehet\u0151s\u00e9g szerinti sz\u00fcneteltet\u00e9s\u00e9re. Prevenci\u00f3s int\u00e9zked\u00e9s a magas\n                    rizik\u00f3val b\u00edr\u00f3 betegek eset\u00e9ben javasolt intrav\u00e9n\u00e1s hidr\u00e1l\u00e1s form\u00e1j\u00e1ban,\n                    fiziol\u00f3gi\u00e1s koncentr\u00e1ci\u00f3j\u00fa n\u00e1trium-klorid vagy n\u00e1trium-bikarbon\u00e1t inf\u00fazi\u00f3j\u00e1val.\n                    Az egy\u00e9b elj\u00e1r\u00e1sok hat\u00e1stalanok, \u00e9s nem indokolt a beavatkoz\u00e1s ut\u00e1ni dial\u00edzis\n                    v\u00e9gz\u00e9se sem v\u00e9gst\u00e1dium\u00fa veseel\u00e9gtelen betegekben. A metformint 60 ml\/min\/1,73\n                        m<jats:sup>2<\/jats:sup> feletti eGFR-rel rendelkez\u0151 beteg vizsg\u00e1lata kapcs\u00e1n\n                    sz\u00fcks\u00e9gtelen elhagyni, ett\u0151l rosszabb vesem\u0171k\u00f6d\u00e9s eset\u00e9n kell sz\u00fcneteltetni.\n                    Amennyiben a vizsg\u00e1lat indik\u00e1ci\u00f3ja s\u00fcrg\u0151ss\u00e9gi, az a metformin egyidej\u0171\n                    elhagy\u00e1s\u00e1val elv\u00e9gezhet\u0151, de a gy\u00f3gyszer csak 48 \u00f3ra m\u00falva, az akut\n                    vesek\u00e1rosod\u00e1s kiz\u00e1r\u00e1s\u00e1t k\u00f6vet\u0151en adhat\u00f3 vissza. Orv Hetil. 2022; 163(3):\n                    83\u201391.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold> In the current clinical practice, studies with iodinated\n                    contrast agents are often limited in patients with kidney disease and delayed in\n                    those on metformin therapy due to fear of contrast-induced acute kidney injury\n                    (CI-AKI). We aim to review the most recent information about CI-AKI and provide\n                    recommendations in order to avoid cancellation of important contrast-enhanced\n                    tests, but maximize safety considerations. According to the most recent\n                    findings, CI-AKI occurs less frequently nowadays than previously, and depends\n                    significantly on the route of contrast administration (intraarterial or\n                    intravenous). The most important risk factor is the decreased GFR, which, in\n                    stable patients with intravenous contrast administration provides high risk if\n                    the eGFR is less than 30 ml\/min\/1.73 m<jats:sup>2<\/jats:sup>, and with intraarterial\n                    contrast is less than 45 ml\/min\/1.73 m<jats:sup>2<\/jats:sup>. In patients with\n                    proteinuria, the risk of both CI-AKI and CA-AKI (contrast-associated kidney\n                    injury) is increased, therefore urinary albumin\/creatinine or protein\/creatinine\n                    ratios are recommended to measure before the contrast material administration,\n                    beside the eGFR determination. Unstable condition, acute renal failure always\n                    mean high risk; in these cases, eGFR calculation is imprecise and useless. If\n                    renal function is decreased, the amount of contrast material needs\n                    consideration, repeated contrast-enhanced studies should be avoided in 48\u201372\n                    hours, the non-steroidal anti-inflammatory agents and other nephrotoxic drugs\n                    have to be discontinued. For high risk patients, preventive intravenous\n                    hydration should be given, either by physiologic saline or sodium bicarbonate\n                    infusion. Other drugs aiming prevention have proved to be useless; dialysis\n                    treatment immediately after contrast administration in end-stage renal disease\n                    patients is unnecessary. There is no indication to discontinue metformin if eGFR\n                    is higher than 60 ml\/min\/1.73 m<jats:sup>2<\/jats:sup>, but if the patient has less than\n                    that value, the metformin needs to be stopped. In urgent studies with contrast\n                    agent, metformin administration has to be discontinued simultaneously with the\n                    intervention, and this drug can only be readministered after ruling out acute\n                    kidney injury in 48 hours following contrast exposure. Orv Hetil. 2022; 163(3):\n                    83\u201391.<\/jats:p>","DOI":"10.1556\/650.2022.32364","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T22:02:31Z","timestamp":1642543351000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":2,"title":["Radioj\u00f3d kontrasztanyagok \u00e1ltal okozott vesek\u00e1rosod\u00e1s \u00e9s megel\u0151z\u00e9se az \u00fajabb irodalmi adatok t\u00fckr\u00e9ben."],"prefix":"10.1556","volume":"163","author":[{"given":"\u00c1gnes","family":"Haris","sequence":"first","affiliation":[{"name":"P\u00e9terfy K\u00f3rh\u00e1z-Rendel\u0151int\u00e9zet \u00e9s Manninger Jen\u0151 Orsz\u00e1gos Traumatol\u00f3giai Int\u00e9zet, I. Belgy\u00f3gy\u00e1szat, Nephrologia \u00e9s Gasztroenterol\u00f3gia Oszt\u00e1ly Budapest, P\u00e9terfy S. u. 8\u201320., 1076"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"M\u00e1tyus","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Belgy\u00f3gy\u00e1szati Int\u00e9zet, Nephrol\u00f3giai Tansz\u00e9k Debrecen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1053\/j.ackd.2017.03.001","article-title":"Intravenous contrast-induced nephropathy - the rise and fall of a threatening idea","volume":"24","author":"1 Luk","year":"2017","unstructured":"1 Luk L, Steinman J, Newhouse JH. Intravenous contrast-induced nephropathy - the rise and fall of a threatening idea. Adv Chronic Kidney Dis. 2017; 24: 169-175.","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1179546819878680","DOI":"10.1177\/1179546819878680","article-title":"Contrast-induced acute kidney injury: review and practical update","volume":"13","author":"2 Morcos","year":"2019","unstructured":"2 Morcos R, Kucharik M, Bansal P, et al. Contrast-induced acute kidney injury: review and practical update. Clin Med Insights Cardiol. 2019; 13: 1179546819878680.","journal-title":"Clin Med Insights Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1016\/j.amjcard.2017.08.036","article-title":"Impact of transient or persistent contrast-induced nephropathy on long-term mortality after elective percutaneous coronary intervention","volume":"120","author":"3 Abe","year":"2017","unstructured":"3 Abe M, Morimoto T, Nakagawa Y, et al. Impact of transient or persistent contrast-induced nephropathy on long-term mortality after elective percutaneous coronary intervention. Am J Cardiol. 2017; 120: 2146-2153.","journal-title":"Am J Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.amjms.2017.05.010","article-title":"Contrast-induced nephropathy after cardiac catheterization: culprits, consequences and predictors","volume":"354","author":"4 Sedhai","year":"2017","unstructured":"4 Sedhai YR, Golamari R, Timalsina S, et al. Contrast-induced nephropathy after cardiac catheterization: culprits, consequences and predictors. Am J Med Sci. 2017; 354: 462-466.","journal-title":"Am J Med Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1053\/j.ackd.2017.03.003","article-title":"Intravenous contrast: friend or foe? A review on contrast-induced nephropathy","volume":"24","author":"5 Do","year":"2017","unstructured":"5 Do C. Intravenous contrast: friend or foe? A review on contrast-induced nephropathy. Adv Chronic Kidney Dis. 2017; 24: 147-149.","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1148\/radiol.14132418","article-title":"Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality","volume":"273","author":"6 McDonald","year":"2014","unstructured":"6 McDonald RJ, McDonald JS, Carter RE, et al. Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality. Radiology 2014; 273: 714-725.","journal-title":"Radiology"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7 Park S, Kim MH, Kang E, et al. Contrast-induced nephropathy after computed tomography in stable CKD patients with proper prophylaxis: 8-year experience of outpatient prophylaxis program. Medicine (Baltimore) 2016; 95: e3560.","DOI":"10.1097\/MD.0000000000003560"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1007\/s00330-017-5247-4","article-title":"Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: recommendations for updated ESUR Contrast Medium Safety Committee guidelines","volume":"28","author":"8 van der Molen","year":"2018","unstructured":"8 van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018; 28: 2856-2869.","journal-title":"Eur Radiol"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9 McDonald RJ, McDonald JS, Newhouse JH, et al. Controversies in contrast material-induced acute kidney injury: closing in on the truth? Radiology 2015; 277: 627-632.","DOI":"10.1148\/radiol.2015151486"},{"key":"ref9","unstructured":"10 Haris \u00c1, Nagy J, M\u00e1tyus J. Recommendations for prevention of contrast-induced nephropathy. Clinical guideline. [\u00c1ll\u00e1sfoglal\u00e1s a kontrasztanyagok vesek\u00e1ros\u00edt\u00f3 hat\u00e1s\u00e1nak megel\u0151z\u00e9s\u00e9re. Szakmai ir\u00e1nyelv.] Hyperton Nephrol. 2012; 16: 163-166. [Hungarian]"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1148\/radiol.2019192094","article-title":"Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation","volume":"294","author":"11 Davenport","year":"2020","unstructured":"11 Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020; 294: 660-668.","journal-title":"Radiology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s00330-017-5246-5","article-title":"Part 1: definition, clinical features, incidence, role of contrast medium and risk factors: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines","volume":"28","author":"12 van der Molen","year":"2018","unstructured":"12 van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury. Part 1: definition, clinical features, incidence, role of contrast medium and risk factors: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018; 28: 2845-2855.","journal-title":"Eur Radiol"},{"key":"ref12","unstructured":"13 European Society of Urogenital Radiology. ESUR guidelines on contrast agents. 10.0. Section B. Renal adverse reactions (post-contrast acute kidney injury, PC-AKI). Contrast Media Safety Committee, March 2018; pp. 17-25."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.31083\/j.rcm.2020.01.44","article-title":"Contrast induced acute kidney injury in interventional cardiology: an update and key guidance for clinicians","volume":"21","author":"14 Ronco","year":"2020","unstructured":"14 Ronco F, Tarantini G, McCullough PA. Contrast induced acute kidney injury in interventional cardiology: an update and key guidance for clinicians. Rev Cardiovasc Med. 2020; 21: 9-23.","journal-title":"Rev Cardiovasc Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1056\/NEJMra1805256","article-title":"Contrast-associated acute kidney injury","volume":"380","author":"15 Mehran","year":"2019","unstructured":"15 Mehran R, Dangas GD, Weisbord SD. Contrast-associated acute kidney injury. N Engl J Med. 2019; 380: 2146-2155.","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.jacc.2016.05.099","article-title":"Contrast-induced acute kidney injury","volume":"68","author":"16 McCullough","year":"2016","unstructured":"16 McCullough PA, Choi JP, Feghali GA, et al. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2016; 68: 1465-1473.","journal-title":"J Am Coll Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17 Hsieh MS, Chiu CS, How CK, et al. Contrast medium exposure during computed tomography and risk of development of end-stage renal disease in patients with chronic kidney disease: a nationwide population-based, propensity score-matched, longitudinal follow-up study. Medicine (Baltimore) 2016; 95: e3388.","DOI":"10.1097\/MD.0000000000003388"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18 Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011; 80: 17-28. [Erratum: Kidney Int. 2011; 80: 1000.]","DOI":"10.1038\/ki.2010.483"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1136\/neurintsurg-2016-012349","article-title":"Proteinuria as an independent risk factor for contrast-induced acute kidney injury and mortality in patients with stroke undergoing cerebral angiography","volume":"9","author":"19 Tao","year":"2017","unstructured":"19 Tao Y, Dong W, Li Z, et al. Proteinuria as an independent risk factor for contrast-induced acute kidney injury and mortality in patients with stroke undergoing cerebral angiography. J Neurointerv Surg. 2017; 9: 445-448.","journal-title":"J Neurointerv Surg"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/0886022X.2017.1349673","article-title":"The predictive value of the product of contrast medium volume and urinary albumin\/creatinine ratio in contrast-induced acute kidney injury","volume":"39","author":"20 Wang","year":"2017","unstructured":"20 Wang C, Ma S, Deng B, et al. The predictive value of the product of contrast medium volume and urinary albumin\/creatinine ratio in contrast-induced acute kidney injury. Ren Fail. 2017; 39: 555-560.","journal-title":"Ren Fail"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1253\/circj.CJ-14-1345","article-title":"Proteinuria and reduced estimated glomerular filtration rate are independent risk factors for contrast-induced nephropathy after cardiac catheterization","volume":"79","author":"21 Saito","year":"2015","unstructured":"21 Saito Y, Watanabe M, Aonuma K, et al. CINC-J study investigators. Proteinuria and reduced estimated glomerular filtration rate are independent risk factors for contrast-induced nephropathy after cardiac catheterization. Circ J. 2015; 79: 1624-1630.","journal-title":"Circ J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.amjmed.2015.02.018","article-title":"Intravenous imaging contrast media complications: the basics that every clinician needs to know","volume":"128","author":"Rose TA Jr","year":"2015","unstructured":"22 Rose TA Jr, Choi JW. Intravenous imaging contrast media complications: the basics that every clinician needs to know. Am J Med. 2015; 128: 943-949.","journal-title":"Am J Med"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23 Negishi Y, Tanaka A, Ishii H, et al. Contrast-induced nephropathy and long-term clinical outcomes following percutaneous coronary intervention in patients with advanced renal dysfunction (estimated glomerular filtration rate <30 ml\/min\/1.73 m2). Am J Cardiol. 2019; 123: 361-367.","DOI":"10.1016\/j.amjcard.2018.10.038"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24 He H, Chen XR, Chen YQ, et al. Prevalence and predictors of contrast-induced nephropathy (CIN) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI): a meta-analysis. J Interv Cardiol. 2019; 2019: 2750173.","DOI":"10.1155\/2019\/2750173"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12872-019-1054-y","article-title":"Effects of intravenous hydration on risk of contrast induced nephropathy and in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"25 Liu","year":"2019","unstructured":"25 Liu Y, Hong D, Wang AY, et al. Effects of intravenous hydration on risk of contrast induced nephropathy and in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2019; 19: 87.","journal-title":"BMC Cardiovasc Disord"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26 Cai Q, Jing R, Zhang W, et al. Hydration strategies for preventing contrast-induced acute kidney injury: a systematic review and bayesian network meta-analysis. J Interv Cardiol. 2020; 2020: 7292675.","DOI":"10.1155\/2020\/7292675"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S0140-6736(17)30057-0","article-title":"Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial","volume":"389","author":"27 Nijssen","year":"2017","unstructured":"27 Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 2017; 389: 1312-1322.","journal-title":"Lancet"},{"key":"ref27","unstructured":"28 Weisbord SD, Gallagher M, Jneid H, et al., PRESERVE Trial Group. Outcomes after angiography with sodium bicarbonate and acetylcysteine. Lancet 2017; 389: 1312-1322."},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29 Cho A, Lee YK, Sohn SY. Beneficial effect of statin on preventing contrast-induced acute kidney injury in patients with renal insufficiency: a meta-analysis. Medicine (Baltimore) 2020; 99: e19473.","DOI":"10.1097\/MD.0000000000019473"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30 Liang M, Yang S, Fu N. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: a meta-analysis of 15 randomized controlled trials. Medicine (Baltimore) 2017; 96: e7384.","DOI":"10.1097\/MD.0000000000007384"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31 Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC Scientific Document Group. 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019; 40: 87-165. [Erratum: Eur Heart J. 2019; 40: 3096.]","DOI":"10.1093\/eurheartj\/ehy855"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ahj.2015.04.019","article-title":"Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: results from the angiotensin converting enzyme inhibitor\/angiotensin receptor blocker and contrast induced nephropathy in patients receiving cardiac catheterization (CAPTAIN) trial","volume":"170","author":"32 Bainey","year":"2015","unstructured":"32 Bainey KR, Rahim S, Etherington K, et al., CAPTAIN Investigators. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: results from the angiotensin converting enzyme inhibitor\/angiotensin receptor blocker and contrast induced nephropathy in patients receiving cardiac catheterization (CAPTAIN) trial. Am Heart J. 2015; 170: 110-116.","journal-title":"Am Heart J"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jacc.2007.03.058","article-title":"Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention","volume":"50","author":"33 Laskey","year":"2007","unstructured":"33 Laskey WK, Jenkins C, Selzer F, et al., NHLBI Dynamic Registry Investigators. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol. 2007; 50: 584-590.","journal-title":"J Am Coll Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34 Zhang J, Jiang Y, Rui Q, et al. Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI. Medicine (Baltimore) 2018; 97: e0617.","DOI":"10.1097\/MD.0000000000010617"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40644-019-0224-6","article-title":"Comparative effect of iso-osmolar versus low-osmolar contrast media on the incidence of contrast-induced acute kidney injury in diabetic patients: a systematic review and meta-analysis","volume":"19","author":"35 Zhao","year":"2019","unstructured":"35 Zhao F, Lei R, Yang SK, et al. Comparative effect of iso-osmolar versus low-osmolar contrast media on the incidence of contrast-induced acute kidney injury in diabetic patients: a systematic review and meta-analysis. Cancer Imaging 2019; 19: 38.","journal-title":"Cancer Imaging"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa021833","article-title":"Nephrotoxic effects in high-risk patients undergoing angiography","volume":"348","author":"36 Aspelin","year":"2003","unstructured":"36 Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003; 348: 491-499.","journal-title":"N Engl J Med"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/3\/article-p83.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/3\/article-p83.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/3\/article-p83.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T08:38:18Z","timestamp":1698223098000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/3\/article-p83.xml"}},"subtitle":["V\u00e1ltoztassunk a gyakorlaton!"],"short-title":[],"issued":{"date-parts":[[2022,1,16]]},"references-count":36,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1556\/650.2022.32364","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,16]]}}}